Quality of life and symptom control for non-squamous NSCLC patients on nivolumab (CheckMate 057)
What is durvalumab’s future as a treatment option in lung cancer?
Acquired resistance to third-generation EGFR TKIs in NSCLC
Data update in advanced stage NSCLC
TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer